NCT01429740已完成1 期
A Phase 1, Placebo-Controlled, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-05180999 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Composite (or profile) of Pharmacokinetics
研究概览
简要总结
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •male or female of non-childbearing potential,
排除标准
- •Evidence of clinically significant medical illness, history of seizures, any condition possibly affecting drug absorption
研究组 & 干预措施
PF-05180999
Experimental
干预措施: PF-05180999 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Composite (or profile) of Pharmacokinetics
时间窗: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose on Day 1 and Day 1
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy ParticipantsAutosomal Dominant Polycystic Kidney Disease (ADPKD)NCT06345755Vertex Pharmaceuticals Incorporated159
已完成
1 期
Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 DiabetesDiabetes Mellitus Type 2NCT00924053Theracos24
已完成
1 期
A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy VolunteersHealthy VolunteersNCT01954238Green Cross Corporation46
已完成
1 期
A Phase 1 Dose Escalation Study of VX-973 in Healthy ParticipantsPainNCT06615570Vertex Pharmaceuticals Incorporated30
已完成
1 期
A Phase 1 Dose Escalation Study of VX-973 in Healthy AdultsPainNCT05866055Vertex Pharmaceuticals Incorporated30